Krystal Biotech, Inc. (NASDAQ:KRYS) Given Consensus Recommendation of "Buy" by Brokerages

Shares of Krystal Biotech, Inc. (NASDAQ:KRYS - Get Free Report) have received an average recommendation of "Buy" from the eight brokerages that are currently covering the company, Marketbeat reports. One investment analyst has rated the stock with a hold recommendation, six have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1 year price target among brokers that have covered the stock in the last year is $210.00.

Several research analysts have recently weighed in on the company. Chardan Capital upped their target price on Krystal Biotech from $212.00 to $218.00 and gave the stock a "buy" rating in a research note on Thursday. Citigroup boosted their price target on Krystal Biotech from $206.00 to $215.00 and gave the stock a "neutral" rating in a research report on Thursday. HC Wainwright reiterated a "buy" rating and set a $221.00 price target on shares of Krystal Biotech in a research report on Wednesday. Finally, Cantor Fitzgerald reiterated an "overweight" rating and set a $215.00 price target on shares of Krystal Biotech in a research report on Thursday.

Insider Buying and Selling at Krystal Biotech

In other news, insider Suma Krishnan sold 25,000 shares of the company's stock in a transaction on Friday, December 13th. The stock was sold at an average price of $164.78, for a total value of $4,119,500.00. Following the transaction, the insider now owns 1,475,882 shares of the company's stock, valued at $243,195,835.96. This represents a 1.67 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. 14.10% of the stock is owned by company insiders.

Hedge Funds Weigh In On Krystal Biotech

Several large investors have recently modified their holdings of KRYS. Norges Bank acquired a new position in shares of Krystal Biotech in the 4th quarter valued at $34,391,000. Soleus Capital Management L.P. lifted its stake in Krystal Biotech by 65.2% during the 4th quarter. Soleus Capital Management L.P. now owns 358,379 shares of the company's stock worth $56,144,000 after acquiring an additional 141,400 shares in the last quarter. Segall Bryant & Hamill LLC lifted its stake in Krystal Biotech by 352.4% during the 3rd quarter. Segall Bryant & Hamill LLC now owns 157,144 shares of the company's stock worth $28,605,000 after acquiring an additional 122,407 shares in the last quarter. State Street Corp lifted its stake in Krystal Biotech by 9.0% during the 3rd quarter. State Street Corp now owns 1,452,811 shares of the company's stock worth $264,455,000 after acquiring an additional 119,936 shares in the last quarter. Finally, Raymond James Financial Inc. acquired a new position in Krystal Biotech during the 4th quarter worth about $15,989,000. Institutional investors and hedge funds own 86.29% of the company's stock.

Krystal Biotech Stock Up 2.5 %

Shares of KRYS stock traded up $4.48 during trading hours on Thursday, hitting $187.10. 155,885 shares of the company's stock were exchanged, compared to its average volume of 256,481. The firm has a market cap of $5.38 billion, a P/E ratio of 62.57 and a beta of 0.84. The firm has a 50 day moving average of $157.37 and a two-hundred day moving average of $175.23. Krystal Biotech has a fifty-two week low of $107.50 and a fifty-two week high of $219.34.

Krystal Biotech (NASDAQ:KRYS - Get Free Report) last announced its earnings results on Monday, February 24th. The company reported $1.52 earnings per share for the quarter, topping the consensus estimate of $1.29 by $0.23. The business had revenue of $91.10 million during the quarter, compared to the consensus estimate of $91.35 million. Krystal Biotech had a return on equity of 11.41% and a net margin of 30.69%. The business's quarterly revenue was up 116.4% on a year-over-year basis. During the same period in the prior year, the company posted $0.30 EPS. On average, equities analysts forecast that Krystal Biotech will post 6.14 earnings per share for the current fiscal year.

About Krystal Biotech

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).